Wee1
Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe). Wee1 has amolecular mass of 96 kDa and it is a key regulator of cell cycle progression. Wee1 influences cell size by inhibiting the entry into mitosis, through inhibiting Cdk1. Wee1 has homologues in many other organisms, including mammals. Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14. Cdk1 is crucial for the cyclin-dependent passage of the various cell cycle checkpoints. At least three checkpoints exist for which the inhibition of Cdk1 by Wee1 is important: G2/M checkpoint, Cell size checkpoint, DNA damage checkpoint. Wee1 is shown to phosphorylate histone H2B at tyrosine 37 residue which regulates global expression of histones.
WEE1 subfamily includes PMYT1.
WEE1 subfamily includes PMYT1.
Wee1 Isoform Specific Products
All Product Categories
-
Wee1 Related Products (82)
Related Products (82)
-
Wee1 Isoform Comparison
-
WEE1-IN-8
0 ImagesCat. No.: HY-161871CAS No.: 2493422-74-3WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC50 of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc.
-
AZD1775-C3-NH2
0 ImagesCat. No.: HY-133703CAS No.: 2101954-45-2AZD1775-C3-NH2 is a Target Protein Ligand-Linker Conjugate that contains a target protein ligand and a PROTAC linker, and can recruit E3 ligases. AZD1775-C3-NH2 can be used for the synthesis of Pomalidomide-C3-adavosertib (HY-133618).
-
Adavosertib-C3-NH-Boc
0 ImagesCat. No.: HY-176363CAS No.: 2113725-19-0Adavosertib-C3-NH-Boc is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for Wee1 (HY-10993) and a PROTAC linker (HY-W011561), which recruits E3 ligases. Adavosertib-C3-NH-Boc can be used for synthesis of PROTAC Pomalidomide-C3-adavosertib (HY-133618).
-
PKMYT1-IN-11
0 ImagesCat. No.: HY-176957CAS No.: 3097325-25-9PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC50 of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer.
-
CJM061
0 ImagesCat. No.: HY-182433CAS No.: 1847445-87-7CJM061 is a WEE1 kinase inhibitor with a target IC50 of 2.8 nM. CJM061 acts as a sensitizer and exhibits synergistic effects with Cisplatin (HY-17394) in medulloblastoma cells. CJM061 can be used for the research of medulloblastoma.
-
Tubulin/LSD1-IN-1
0 ImagesCat. No.: HY-176283Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC50 = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells.
-
WEE1-IN-11
0 ImagesCat. No.: HY-168180CAS No.: 2975172-98-4WEE1-IN-11 (Compound 13) is a potent CDK2 inhibitor with an IC50 of 2.0 nM. WEE1-IN-11 inhibits NCI–H446, A427, OVCAR3, C33A,and WiDr cells with IC50s of 93.9, 34.5, 86.7, 23.1, and 85 nM, respectively.
-
LEB-03-153
0 ImagesCat. No.: HY-143343CAS No.: 2858812-88-9
-
DB07006
0 ImagesCat. No.: HY-160948CAS No.: 622855-60-1DB07006 (compound 18) is a potent, ATP-cpmpetitive dual inhibitor of Wee1 (IC50 = 0.030 μM) and Chk1 checkpoint kinases (IC50 = 0.018 μM). DB07006 demonstrates effective abrogation of the G2/M checkpoint in combination with DNA-damaging agents in cellular models. DB07006 can be used for cancer research.
-
XH-30
0 ImagesCat. No.: HY-180893CAS No.: 3077136-87-6XH-30 is a potent, selective, and orally active PKMYT1 inhibitor, with an IC50 of 4.1 nM. XH-30 suppresses the proliferation of P53-mutated triple-negative breast cancer (TNBC) cells by inducing G2/M phase release, DNA damage, and apoptosis. XH-30 demonstrates antitumor effects in an MDA-MB-231 mouse model. XH-30 can be used for P53-mutated TNBC research.
-
WEE1-IN-4 (Standard)
0 ImagesCat. No.: HY-108343RCAS No.: 622855-37-2
-
Sirusertib
0 ImagesCat. No.: HY-188057CAS No.: 3066062-53-8Sirusertib (WEE1A&Myt1-IN-1) is a dual Wee1A/Myt1 inhibitor, with an IC50 of ≤10 nM against Wee1A and ≤20 nM against Myt1. Sirusertib is applicable for cancer-related research.
-
PKMYT1-IN-4
0 ImagesCat. No.: HY-162986CAS No.: 3047617-07-9PKMYT1-IN-4 (compund 27) is a PKMYT1 inhibitor with IC50 less than 50 nM.
-
Raddeanin A (Standard)
0 ImagesCat. No.: HY-N0819RCAS No.: 89412-79-3Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
-
PKMYT1-IN-7
0 ImagesCat. No.: HY-159937CAS No.: 2986404-30-0PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both< and <.
-
Myt1-IN-6
0 ImagesCat. No.: HY-176853CAS No.: 3056083-14-5Myt1-IN-6 (Compound formula (1)) is a highly selective MYT1 kinase inhibitor. Myt1-IN-6 is promising for research of RB1-deficient cancers (e.g., triple-negative breast cancer).
